AstraZeneca PLCAZNNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 5.43% |
| Q3 2025 | 3.24% |
| Q2 2025 | 12.31% |
| Q1 2025 | -32.46% |
| Q4 2024 | 50.14% |
| Q3 2024 | 3.56% |
| Q2 2024 | 8.08% |
| Q1 2024 | -9.44% |
| Q4 2023 | 18.92% |
| Q3 2023 | -3.11% |
| Q2 2023 | 2.14% |
| Q1 2023 | -6.35% |
| Q4 2022 | 13.43% |
| Q3 2022 | -3.46% |
| Q2 2022 | 19.36% |
| Q1 2022 | -48.54% |
| Q4 2021 | 14.82% |
| Q3 2021 | 97.38% |
| Q2 2021 | 6.77% |
| Q1 2021 | -16.36% |
| Q4 2020 | 36.99% |
| Q3 2020 | 7.63% |
| Q2 2020 | 0.07% |
| Q1 2020 | -36.13% |
| Q4 2019 | 61.44% |
| Q3 2019 | -0.74% |
| Q2 2019 | 7.11% |
| Q1 2019 | -37.08% |
| Q4 2018 | 62.00% |
| Q3 2018 | -8.81% |
| Q2 2018 | 6.49% |
| Q1 2018 | -17.54% |
| Q4 2017 | 10.47% |
| Q3 2017 | 4.08% |
| Q2 2017 | -7.16% |
| Q1 2017 | -5.83% |
| Q4 2016 | 10.06% |
| Q3 2016 | -4.30% |
| Q2 2016 | -1.01% |
| Q1 2016 | -15.23% |